- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04693676
A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma
A Phase 1 Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Subjects With Relapsed and/or Refractory NHL
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-arm, open label, "3+3" dose escalation, phase I study to evaluate the safety and preliminary efficacy of C-CAR039 in adults with relapsed/refractory B-cell Non-Hodgkin's Lymphoma. 10 patients are planned to be enrolled.
Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of C-CAR039. Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to C-CAR039 infusion. All subjects who have received C-CAR039 infusion will be followed for up to 24 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- The First Affiliated Hospital, College of Medicine, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient volunteered to participate in the study and signed the Informed Consent;
- Age between 18 and 70 (including 18 and 70), male or female;
- Expected survival ≥ 12 weeks;
- ECOG score 0-2
- CD19 or CD20 positive B-NHL confirmed by cytology or histology according to WHO2016 criteria, including DLBCL, PMBCL, tFL, FL and MCL;
- Relapsed or refractory disease after ≥ 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT)
- For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause of intolerance should be recorded;
- No contraindications of apheresis;
- At least one measurable lesion according to Lugano 2014 criteria;
- Adequate organ function.
Exclusion Criteria:
- Malignant tumors other than B-NHL within 5 years prior to screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery;
- Active HIV, HBV, HCV or treponema pallidum infection ;
- Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy;
- Any uncontrolled, active disease that prevents participation in the trial;
- Female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after their cell transfusion;
- Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment;
- Patients who have been previously infected with tuberculosis;
- Administered Corticosteroids and/or other immunosuppressants within 7 days before apheresis. and 5 days before the infusion of C-CAR039;
- Patients with central nervous system involvement;
- Any systemic antitumor therapy was performed within 2 weeks before conditional treatment chemotherapy pretreatment;
- Any situation that the investigator believes would compromise the safety of the subject or interfere with the purpose of the study;
- Those with medical conditions that prevent them from signing the written informed consent or from complying with the study procedures; or those who are unwilling or unable to comply with the study requirements.
- Other conditions deemed unsuitable for enrollment by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prizloncabtagene autoleucel
Prizlon-cel will be intravenously administered as a single infusion after lymphodepletion
|
Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD
Time Frame: Up to 24 months after C-CAR039 infusion
|
maximum tolerated dose or clinical recommended dose
|
Up to 24 months after C-CAR039 infusion
|
DLT
Time Frame: Up to 28 days after C-CAR039 infusion
|
Dose limiting toxicity
|
Up to 28 days after C-CAR039 infusion
|
AE/SAE/AESI
Time Frame: Up to 24 months after C-CAR039 infusion
|
adverse events (AE), serious adverse event (SAE), adverse events of sepical interest (AESI) (including cytokine release syndrome (CRS), and nerve toxicity), laboratory tests (type, frequency and severity), vital signs and ECG abnormality rate.
|
Up to 24 months after C-CAR039 infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
C-CAR039 CAR expansion and persistence
Time Frame: Up to 24 Months after C-CAR039 infusion
|
After C-CAR039 infusion, peripheral blood EXP039 CAR expansion and persistence in vivo, including Cmax, Tmax, AUC0-28day, Tlast
|
Up to 24 Months after C-CAR039 infusion
|
Overall response rate (ORR)
Time Frame: Up to 24 Months after C-CAR039 infusion
|
Complete response (CR) rate plus partial response (PR) rate by Lugano 2014 criteria
|
Up to 24 Months after C-CAR039 infusion
|
Duration of response (DOR)
Time Frame: Up to 24 Months after C-CAR039 infusion
|
The time from the date of first response (PR or better) to the date of disease progression or death after C-CAR039 infusion
|
Up to 24 Months after C-CAR039 infusion
|
Progression-free survival (PFS)
Time Frame: Up to 24 Months after C-CAR039 infusion
|
The time from C-CAR039 infusion to the date of progression as assessed by Lugano 2014 criteria or death
|
Up to 24 Months after C-CAR039 infusion
|
Overall survival (OS)
Time Frame: Up to 24 Months after C-CAR039 infusion
|
The time from C-CAR039 infusion to the date of death
|
Up to 24 Months after C-CAR039 infusion
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jie Jin, PhD&MD, First Affiliated Hospital of Zhejiang University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0702-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's B-cell Lymphoma
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Non-Hodgkin's Lymphoma | Intermediate Grade B-Cell Non-Hodgkin's LymphomaUnited States
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
Debiopharm International SACompletedDiffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's LymphomaUnited States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
-
Eden BioCell Ltd.National Taiwan University HospitalTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryTaiwan
-
Peking UniversityPeking University Cancer Hospital & InstituteRecruitingB Cell Non-Hodgkin's LymphomaChina
-
Peking UniversityUnknownB-cell Non-Hodgkin's Lymphoma
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Not yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
-
Hutchison Medipharma LimitedRecruiting
Clinical Trials on Prizloncabtagene Autoleucel
-
Tianjin Medical University Cancer Institute and...Cellular Biomedicine Group Ltd.Active, not recruitingNon-Hodgkin's B-cell LymphomaChina
-
Cellular Biomedicine Group Ltd.RecruitingRelapsed/Refractory Large B-Cell LymphomaChina
-
Shanghai Tongji Hospital, Tongji University School...Cellular Biomedicine Group Ltd.Active, not recruitingNon-Hodgkin's B-cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.Recruiting
-
AdaptimmuneRecruitingOsteosarcoma | Neuroblastoma | Synovial Sarcoma | Malignant Peripheral Nerve Sheath Tumor (MPNST)United States
-
Peking University People's HospitalNot yet recruitingRelapsed/Refractory Multiple MyelomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.Not yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Large B-cell LymphomaChina
-
Shanghai Ming Ju Biotechnology Co., Ltd.The First Affiliated Hospital with Nanjing Medical UniversityNot yet recruiting
-
Kite, A Gilead CompanyAvailableAcute Lymphoblastic Leukemia | Mantle Cell LymphomaUnited States
-
AdaptimmuneRecruitingMyxoid Liposarcoma | Synovial SarcomaUnited States, United Kingdom, Canada, France, Spain